Publication

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E., Hospers, G. A. P., van der Wekken, A. J., de Groot, D-J., Schröder, C. P., Fehrmann, R. S. N. & Reyners, A. K. L., 4-May-2020, In : Cancer and metastasis reviews. 39, 3, p. 999-1013 15 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Boonstra, P. A., Wind, T. T., van Kruchten, M., Schuuring, E., Hospers, G. A. P., van der Wekken, A. J., de Groot, D-J., Schröder, C. P., Fehrmann, R. S. N., & Reyners, A. K. L. (2020). Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer and metastasis reviews, 39(3), 999-1013. https://doi.org/10.1007/s10555-020-09876-9

Author

Boonstra, Pieter A ; Wind, Thijs T ; van Kruchten, Michel ; Schuuring, Ed ; Hospers, Geke A P ; van der Wekken, Anthonie J ; de Groot, Derk-Jan ; Schröder, Carolien P ; Fehrmann, Rudolf S N ; Reyners, Anna K L. / Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. In: Cancer and metastasis reviews. 2020 ; Vol. 39, No. 3. pp. 999-1013.

Harvard

Boonstra, PA, Wind, TT, van Kruchten, M, Schuuring, E, Hospers, GAP, van der Wekken, AJ, de Groot, D-J, Schröder, CP, Fehrmann, RSN & Reyners, AKL 2020, 'Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy', Cancer and metastasis reviews, vol. 39, no. 3, pp. 999-1013. https://doi.org/10.1007/s10555-020-09876-9

Standard

Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. / Boonstra, Pieter A; Wind, Thijs T; van Kruchten, Michel; Schuuring, Ed; Hospers, Geke A P; van der Wekken, Anthonie J; de Groot, Derk-Jan; Schröder, Carolien P; Fehrmann, Rudolf S N; Reyners, Anna K L.

In: Cancer and metastasis reviews, Vol. 39, No. 3, 04.05.2020, p. 999-1013.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Boonstra PA, Wind TT, van Kruchten M, Schuuring E, Hospers GAP, van der Wekken AJ et al. Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer and metastasis reviews. 2020 May 4;39(3):999-1013. https://doi.org/10.1007/s10555-020-09876-9


BibTeX

@article{1a5bfd20c8344582b4adab594437cf85,
title = "Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy",
abstract = "Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a small subset of malignancies. Through recent technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By utilization of highly sensitive techniques, tumor-specific mutations in circulating DNA can be detected and circulating tumor DNA (ctDNA) can be quantified. These so-called liquid biopsies provide both molecular information about the genomic composition of the tumor and opportunities to evaluate tumor response during therapy. Quantification of tumor-specific mutations in plasma correlates well with tumor burden. Moreover, with liquid biopsies, it is also possible to detect mutations causing secondary resistance during treatment. This review focuses on the clinical utility of ctDNA as a response and follow-up marker in patients with non-small cell lung cancer, melanoma, colorectal cancer, and breast cancer. Relevant studies were retrieved from a literature search using PubMed database. An overview of the available literature is provided and the relevance of ctDNA as a response marker in anti-cancer therapy for clinical practice is discussed. We conclude that the use of plasma-derived ctDNA is a promising tool for treatment decision-making based on predictive testing, detection of resistance mechanisms, and monitoring tumor response. Necessary steps for translation to daily practice and future perspectives are discussed.",
keywords = "ctDNA, Mutation detection, Therapy monitoring, Follow-up, Driver mutations, CELL-FREE DNA, METASTATIC COLORECTAL-CANCER, MONITOR TREATMENT RESPONSE, LUNG-CANCER, ESR1 MUTATIONS, ACQUIRED-RESISTANCE, LIQUID BIOPSIES, EGFR MUTATIONS, NSCLC PATIENTS, DIGITAL PCR",
author = "Boonstra, {Pieter A} and Wind, {Thijs T} and {van Kruchten}, Michel and Ed Schuuring and Hospers, {Geke A P} and {van der Wekken}, {Anthonie J} and {de Groot}, Derk-Jan and Schr{\"o}der, {Carolien P} and Fehrmann, {Rudolf S N} and Reyners, {Anna K L}",
year = "2020",
month = may,
day = "4",
doi = "10.1007/s10555-020-09876-9",
language = "English",
volume = "39",
pages = "999--1013",
journal = "Cancer and metastasis reviews",
issn = "0167-7659",
publisher = "SPRINGER",
number = "3",

}

RIS

TY - JOUR

T1 - Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy

AU - Boonstra, Pieter A

AU - Wind, Thijs T

AU - van Kruchten, Michel

AU - Schuuring, Ed

AU - Hospers, Geke A P

AU - van der Wekken, Anthonie J

AU - de Groot, Derk-Jan

AU - Schröder, Carolien P

AU - Fehrmann, Rudolf S N

AU - Reyners, Anna K L

PY - 2020/5/4

Y1 - 2020/5/4

N2 - Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a small subset of malignancies. Through recent technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By utilization of highly sensitive techniques, tumor-specific mutations in circulating DNA can be detected and circulating tumor DNA (ctDNA) can be quantified. These so-called liquid biopsies provide both molecular information about the genomic composition of the tumor and opportunities to evaluate tumor response during therapy. Quantification of tumor-specific mutations in plasma correlates well with tumor burden. Moreover, with liquid biopsies, it is also possible to detect mutations causing secondary resistance during treatment. This review focuses on the clinical utility of ctDNA as a response and follow-up marker in patients with non-small cell lung cancer, melanoma, colorectal cancer, and breast cancer. Relevant studies were retrieved from a literature search using PubMed database. An overview of the available literature is provided and the relevance of ctDNA as a response marker in anti-cancer therapy for clinical practice is discussed. We conclude that the use of plasma-derived ctDNA is a promising tool for treatment decision-making based on predictive testing, detection of resistance mechanisms, and monitoring tumor response. Necessary steps for translation to daily practice and future perspectives are discussed.

AB - Response evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a small subset of malignancies. Through recent technological innovations, new methods for measuring tumor burden and treatment response are becoming available. By utilization of highly sensitive techniques, tumor-specific mutations in circulating DNA can be detected and circulating tumor DNA (ctDNA) can be quantified. These so-called liquid biopsies provide both molecular information about the genomic composition of the tumor and opportunities to evaluate tumor response during therapy. Quantification of tumor-specific mutations in plasma correlates well with tumor burden. Moreover, with liquid biopsies, it is also possible to detect mutations causing secondary resistance during treatment. This review focuses on the clinical utility of ctDNA as a response and follow-up marker in patients with non-small cell lung cancer, melanoma, colorectal cancer, and breast cancer. Relevant studies were retrieved from a literature search using PubMed database. An overview of the available literature is provided and the relevance of ctDNA as a response marker in anti-cancer therapy for clinical practice is discussed. We conclude that the use of plasma-derived ctDNA is a promising tool for treatment decision-making based on predictive testing, detection of resistance mechanisms, and monitoring tumor response. Necessary steps for translation to daily practice and future perspectives are discussed.

KW - ctDNA

KW - Mutation detection

KW - Therapy monitoring

KW - Follow-up

KW - Driver mutations

KW - CELL-FREE DNA

KW - METASTATIC COLORECTAL-CANCER

KW - MONITOR TREATMENT RESPONSE

KW - LUNG-CANCER

KW - ESR1 MUTATIONS

KW - ACQUIRED-RESISTANCE

KW - LIQUID BIOPSIES

KW - EGFR MUTATIONS

KW - NSCLC PATIENTS

KW - DIGITAL PCR

U2 - 10.1007/s10555-020-09876-9

DO - 10.1007/s10555-020-09876-9

M3 - Review article

C2 - 32367253

VL - 39

SP - 999

EP - 1013

JO - Cancer and metastasis reviews

JF - Cancer and metastasis reviews

SN - 0167-7659

IS - 3

ER -

ID: 124908724